@phdthesis{Schmid2020,
  author    = {Schmid, Benedikt},
  title     = {Molecular Signaling Mechanisms at the µ-Opioid Receptor},
  doi       = {10.25972/OPUS-17685},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176850},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {To this day, opioids represent the most effective class of drugs for the treatment of severe pain. On a molecular level, all opioids in use today are agonists at the μ-opioid receptor (μ receptor). The μ receptor is a class A G protein-coupled receptor (GPCR). GPCRs are among the biological structures most frequently targeted by pharmaceuticals. They are membrane bound receptors, which confer their signals into the cell primarily by activating a variety of GTPases called G proteins. In the course of the signaling process, the μ receptor will be phosphorylated by GRKs, increasing its affinity for another entity of signaling proteins called β-arrestins (β-arrs). The binding of a β-arr to the activated μ receptor will end the G protein signal and cause the receptor to be internalized into the cell. Past research showed that the μ receptor's G protein signal puts into effect the desired pain relieving properties of opioid drugs, whereas β-arr recruitment is more often linked to adverse effects like obstipation, tolerance, and respiratory depression. Recent work in academic and industrial research picked up on these findings and looked into the possibility of enhancing G protein signaling while suppressing β-arr recruitment. The conceptual groundwork of such approaches is the phenomenon of biased agonism. It appreciates the fact that different ligands can change the relative contribution of any given pathway to the overall downstream signaling, thus enabling not only receptor-specific but even pathway-specific signaling. This work examined the ability of a variety of common opioid drugs to specifically activate the different signaling pathways and quantify it by means of resonance energy transfer and protein complementation experiments in living cells. Phosphorylation of the activated receptor is a central step in the canonical GPCR signaling process. Therefore, in a second step, expression levels of the phosphorylating GRKs were enhanced in search for possible effects on receptor signaling and ligand bias. In short, detailed pharmacological profiles of 17 opioid ligands were recorded. Comparison with known clinical properties of the compounds showed robust correlation of G protein activation efficacy and analgesic potency. Ligand bias (i.e. significant preference of any path- way over another by a given agonist) was found for a number of opioids in native HEK293 cells overexpressing μ receptor and β-arrs. Furthermore, overexpression of GRK2 was shown to fundamentally change β-arr pharmacodynamics of nearly all opioids. As a consequence, any ligand bias as detected earlier was abolished with GRK2 overexpression, with the exception of buprenorhin. In summary, the following key findings stand out: (1) Common opioid drugs exert biased agonism at the μ receptor to a small extent. (2) Ligand bias is influenced by expression levels of GRK2, which may vary between individuals, target tissues or even over time. (3) One of the opioids, buprenorhin, did not change its signaling properties with the overexpression of GRK2. This might serve as a starting point for the development of new opioids which could lack the ability of β-arr recruitment altogether and thus might help reduce adverse side effects in the treatment of severe pain.},
  subject      = {Opiatrezeptor},
  language  = {en}
}
@phdthesis{Mayer2021,
  author    = {Mayer, Stefanie},
  title     = {Differenzierte β-Arrestin2 Rekrutierung am μ-Opioid Rezeptor durch klinisch eingesetzte Opioide},
  doi       = {10.25972/OPUS-24094},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240949},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Opioide geh{\"o}ren zu den potentesten Analgetika f{\"u}r die Behandlung akuter und chronischer Schmerzen, werden jedoch in ihrer Anwendung durch analgetische Toleranz aber auch Nebenwirkungen wie Abh{\"a}ngigkeit, Atemdepression und Obstipation limitiert. Opioid-Analgetika vermitteln dabei nahezu alle klinisch relevanten Wirkungen durch Stimulation des μ-Opioidrezeptors, einem G- Protein-gekoppelten Rezeptor. Die „klassische" Signaltransduktion durch Aktivierung inhibitorischer Gi/0-Proteine kann durch G-Protein gekoppelte Rezeptorkinasen (GRKs) und β-Arrestine negativ reguliert werden. Zus{\"a}tzlich k{\"o}nnen durch β-Arrestin-Bindung an den Rezeptor G-Protein-unabh{\"a}ngige Signalwege aktiviert werden. Die genauen Mechanismen wie β-Arrestin- assoziierte Rezeptordesensibilisierung, -internalisierung und G-Protein- unabh{\"a}ngige Signalwege an der physiologischen Antwort und insbesondere an Toleranzentwicklung und Abh{\"a}ngigkeit von Opioid-Analgetika beteiligt sind, k{\"o}nnen bislang nicht ausreichend erkl{\"a}rt werden. In dieser Arbeit konnte in HEK293-Zellen mit Lebendzell-Konfokalmikroskopie und Luciferase-Komplementierung f{\"u}r 17 Opioide eine differenzierte β-Arrestin2- Rekrutierung zum μ-Opioidrezeptor gezeigt werden. Von den untersuchten Opioiden sind 13 h{\"a}ufig eingesetzte Opioid-Analgetika. Durch die Erstellung detaillierter pharmakologischer Profile ließen sich die Opioide bez{\"u}glich ihres β- Arrestin2-Rekrutierungsverm{\"o}gens in Voll-, Partial und Antagonisten eingruppieren. Bemerkenswert war die fehlende β-Arrestin2-Rekrutierung f{\"u}r Buprenorphin, Tramadol und Tilidin, sodass diese interessante Substanzen f{\"u}r weitere Untersuchungen in physiologischerem Kontext sind. Durch {\"U}berexpression von GRK2 konnte die β-Arrestin2-Rekrutierung insbesondere f{\"u}r Partialagonisten gesteigert werden, was die Abh{\"a}ngigkeit der β-Arrestin- Rekrutierung vom GRK-Expressionslevel, das in verschiedenen Assays und Gewebetypen variieren kann, zeigt. Außerdem konnte ein heterogenes Bild der Rezeptorregulierung demonstriert werden, welches indirekt durch Endozytosehemmung unter Verwendung von Dynamin-Inhibitoren erfasst wurde. Die erhobenen Daten dienen als Ankn{\"u}pfungspunkt f{\"u}r weiteren Arbeiten auf dem Gebiet der μ-Opioidrezeptorregulation. Ein besseres Verst{\"a}ndnis der molekularen Mechanismen ist n{\"o}tig, um sichere und nebenwirkungs{\"a}rmere Opioid-Analgetika entwickeln zu k{\"o}nnen.},
  subject      = {Opiatrezeptor},
  language  = {de}
}